Enemy of My Enemy: A Novel Insect-Specific Flavivirus Offers a Promising Platform for a Zika Virus Vaccine

Simple item page
dc.contributor.authorPorier, Danielle L.en
dc.contributor.authorWilson, Sarah N.en
dc.contributor.authorAuguste, Dawn I.en
dc.contributor.authorLeber, Andrewen
dc.contributor.authorCoutermarsh-Ott, Sherylen
dc.contributor.authorAllen, Irving C.en
dc.contributor.authorCaswell, Clayton C.en
dc.contributor.authorBudnick, James A.en
dc.contributor.authorBassaganya-Riera, Josepen
dc.contributor.authorHontecillas, Raquelen
dc.contributor.authorWeger-Lucarelli, Jamesen
dc.contributor.authorWeaver, Scott C.en
dc.contributor.authorAuguste, A. Jonathanen
dc.date.accessioned2021-10-13T12:29:18Zen
dc.date.available2021-10-13T12:29:18Zen
dc.date.issued2021-10-07en
dc.date.updated2021-10-12T14:18:22Zen
dc.description.abstractVaccination remains critical for viral disease outbreak prevention and control, but conventional vaccine development typically involves trade-offs between safety and immunogenicity. We used a recently discovered insect-specific flavivirus as a vector in order to develop an exceptionally safe, flavivirus vaccine candidate with single-dose efficacy. To evaluate the safety and efficacy of this platform, we created a chimeric Zika virus (ZIKV) vaccine candidate, designated Aripo/Zika virus (ARPV/ZIKV). ZIKV has caused immense economic and public health impacts throughout the Americas and remains a significant public health threat. ARPV/ZIKV vaccination showed exceptional safety due to ARPV/ZIKV’s inherent vertebrate host-restriction. ARPV/ZIKV showed no evidence of replication or translation <i>in vitro</i> and showed no hematological, histological or pathogenic effects <i>in vivo</i>. A single-dose immunization with ARPV/ZIKV induced rapid and robust neutralizing antibody and cellular responses, which offered complete protection against ZIKV-induced morbidity, mortality and in utero transmission in immune-competent and -compromised murine models. Splenocytes derived from vaccinated mice demonstrated significant CD4<sup>+</sup> and CD8<sup>+</sup> responses and significant cytokine production post-antigen exposure. Altogether, our results further support that chimeric insect-specific flaviviruses are a promising strategy to restrict flavivirus emergence via vaccine development.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationPorier, D.L.; Wilson, S.N.; Auguste, D.I.; Leber, A.; Coutermarsh-Ott, S.; Allen, I.C.; Caswell, C.C.; Budnick, J.A.; Bassaganya-Riera, J.; Hontecillas, R.; Weger-Lucarelli, J.; Weaver, S.C.; Auguste, A.J. Enemy of My Enemy: A Novel Insect-Specific Flavivirus Offers a Promising Platform for a Zika Virus Vaccine. Vaccines 2021, 9, 1142.en
dc.identifier.doihttps://doi.org/10.3390/vaccines9101142en
dc.identifier.urihttp://hdl.handle.net/10919/105279en
dc.language.isoenen
dc.publisherMDPIen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectflavivirusen
dc.subjectinsect-specific virusen
dc.subjectvaccineen
dc.subjectZika virusen
dc.subjectcorrelates of protectionen
dc.titleEnemy of My Enemy: A Novel Insect-Specific Flavivirus Offers a Promising Platform for a Zika Virus Vaccineen
dc.title.serialVaccinesen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vaccines-09-01142.pdf
Size:
2.97 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journal Articles, Multidisciplinary Digital Publishing Institute (MDPI)
Destination Area: Global Systems Science (GSS)
Scholarly Works, Biomedical Sciences and Pathobiology
Scholarly Works, Center for Emerging, Zoonotic, and Arthropod-borne Pathogens (CeZAP)
Scholarly Works, Center for One Health Research
Scholarly Works, Entomology
Load more